Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions

2014 ◽  
Vol 37 (11) ◽  
pp. 622-626 ◽  
Author(s):  
Düriye S. Karagöz Özen ◽  
Mehmet A. Ozturk ◽  
Övgü Aydin ◽  
Zeynep H. Turna ◽  
Sennur Ilvan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Receptor Expression

scholarly journals The effect of androgen receptor expression on clinical characterization of metastatic breast cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (5) ◽  
pp. 8693-8706 ◽  
Author(s):  
Ji-Yeon Kim ◽  
Kyunghee Park ◽  
Eunjin Lee ◽  
Hae Hyun Jung ◽  
Jin Seok Ahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Androgen Receptor ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Androgen Receptor Expression

scholarly journals Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer

2019 ◽  
Vol 145 (4) ◽  
pp. 1083-1089 ◽  
Author(s):  
Ingeborg E. Kruijff ◽  
Anieta M. Sieuwerts ◽  
Wendy Onstenk ◽  
Agnes Jager ◽  
Paul Hamberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Androgen Receptor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Androgen Receptor Expression

scholarly journals Androgen receptor expression on circulating tumor cells in metastatic breast cancer

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0185231 ◽  
Author(s):  
Takeo Fujii ◽  
James M. Reuben ◽  
Lei Huo ◽  
Jose Rodrigo Espinosa Fernandez ◽  
Yun Gong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Androgen Receptor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Androgen Receptor Expression

Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1087-1087
Author(s):  
Ingeborg Elisabeth de Kruijff ◽  
Anieta M. Sieuwerts ◽  
Wendy Onstenk ◽  
A. Jager ◽  
Paul Hamberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients

scholarly journals Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression

2021 ◽  
Vol 12 ◽  
Author(s):  
Dingyong Wu ◽  
Shu Tang ◽  
Rong Ye ◽  
Dongmei Li ◽  
Dejian Gu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Shannon Index ◽  
Receptor Expression ◽  
Combination Regimen ◽  
Clinical Biomarkers ◽  
Tcr Repertoire

Breast cancer is one of the most commonly diagnosed malignancies. Although endocrine therapy improves the survival of patients with hormone receptor (HR)-positive breast cancer, the post-endocrine therapy strategy for metastatic breast cancer remains challenging. Herein, we report two patients who benefited from antiestrogen agents combined with an immunotherapy regimen to support the notion that an immunotherapy combination regimen may be a potential treatment for patients with HR-positive metastatic breast cancer post-endocrine therapy. Case 1 involved a patient with relapsed breast cancer with ovarian and brain metastases after endocrine therapy. After undergoing surgery for the ovarian lesions, she received three cycles of chemotherapy. Given that the lesions in the brain did not change, chemotherapy was discontinued. A high T cell receptor (TCR) repertoire (high Shannon index and clonality) was observed in the tumor. Considering the patient's preference and safety, and the efficacy of immunotherapy, she was administered with letrozole combined with pembrolizumab. The patient achieved a partial response, and the progression-free survival (PFS) was more than 21 months. Case 2 involved a patient with breast cancer with multiple bone metastases. After failure of combined radiotherapy and chemotherapy, the patient received tamoxifen combined with pembrolizumab based on the patient's preference and clinical biomarkers of a positive differentiation cluster of eight tumor-infiltrating lymphocytes and a high TCR repertoire (high Shannon index and clonality) in the tumor. The patient's bone pain and biomarkers were relieved after the treatment. The patients completed six cycles of pembrolizumab, and the PFS was more than 21 months. In conclusion, our study confirmed that antiestrogen agents combined with an immunotherapy regimen is a promising treatment for patients with HR-positive metastatic breast cancer.

Detection of androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24096-e24096
Author(s):  
Tanja N. Fehm ◽  
Melissa Neubacher ◽  
Franziska Meier-Stiegen ◽  
Natalia Krawczyk ◽  
Hans Neubauer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients

scholarly journals Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?

2021 ◽  
pp. 54-61
Author(s):  
A. I. Stukan ◽  
A. Y. Goryainova ◽  
E. V. Lymar ◽  
S. V. Sharov ◽  
V. V. Antipova
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Treatment ◽  
Hormone Therapy ◽  
Clonal Selection ◽  
Metastatic Breast ◽  
Breast Cancer Treatment ◽  
Receptor Expression ◽  
Metastatic Focus ◽  
Genetic Characteristics

The problem of metastatic breast cancer treatment is linked with clonal selection both in the process of tumor evolution and under the  influence of  previous treatment. The  analysis of  metastatic niche microenvironment and the  molecular genetic features become essential for treatment individualization. Studies demonstrate hormonal expression and epidermal growth factor receptor (HER2neu) discordance between the primary tumor and the metastatic focus. The advantages of combined hormone therapy (CНT) with CDK4/6 inhibitors were revealed in comparison with hormone therapy (НT) with survival rates benefits in the 1st and 2nd lines of НT, as well as after the 1st line of chemotherapy in clinical trials. However, there are lack of data on patients with multiple lines of chemotherapy. In the present retrospective study, more than half of the patients were treated palliative chemotherapy before administration of CDK4/6 inhibitors. Main metastatic foci represented luminal types after biopsy, however, loss of progesterone receptor expression was noted with the initial luminal A-subtype. At the time of the data cut-off, most patients have a longterm clinical effect, improvement conditions and reduction of pain, including the cases of late line CHT setting after chemotherapeutic regimens. Taking into account the heterogeneity of metastatic breast cancer, clonal selection and phenotype discordance there is the crucial need for molecular and genetic characteristics of the metastatic process. At the same time it is possible to consider the  appointment of  combined hormone therapy with CDK4/6  inhibitors as additional option for  late-line treatment of the disseminated process. Prospective studies on combined hormonal therapy with CDK4/6 inhibitors in metastatic breast cancer in late lines of therapy with proven HR+HER2neu-negative receptor status of the metastatic focus are strongly recommended. 

Sign in / Sign up

Export Citation Format

Share Document